Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Satellos Bioscience Inc.

Satellos Appoints Stephanie Brown to Board of Directors
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Reports Q3 2024 Financial Results and Provides Clinical Update
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Participate in November 2024 Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Demonstrates Treatment of DMD Canines with SAT-3247 Improved Measures of Strength to Near Normal Levels
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Dosing of First Participant in Phase 1 Clinical Study of SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Participation in September 2024 Investor Conferences
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Acceptance of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Q2 2024 Financial Results and Updated Canine Data
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Receives Rare Pediatric Disease Designation from the U.S. FDA for SAT-3247 for the Treatment of Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Submission of Regulatory Filing to Commence a Phase 1 Clinical Trial with SAT-3247
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Presents Preliminary Data Showing Muscle Repair and Regeneration from SAT-3247 Treatment in Canine Model of Duchenne Muscular Dystrophy (“DMD”)
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Presentation at Parent Project Muscular Dystrophy (PPMD) 30th Annual Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Formation of Clinical Advisory Board to Support Advancing SAT-3247 in Clinical Trial Development for Duchenne Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Bioscience Announces Results of Annual and Special Meeting of Shareholders
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Bioscience Announces Q1 2024 Financial Results and Operational Highlights
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Present at the 2024 Bloom Burton & Co. Healthcare Investor Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Bioscience Announces 2023 Year End Financial Results and Operational Highlights
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Present at Upcoming Virtual Investor Conferences in March and April
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Participate in the Leerink Partners Global Biopharma Conference 2024
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Presents Positive Preclinical Efficacy Data for SAT-3247 at the 2024 MDA Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Recognized as a Top 50 TSX Venture Exchange Company
From Satellos Bioscience Inc.
Via Business Wire
Tickers TSX:MSCL
Satellos Announces Upcoming Presentations at the 2024 Muscular Dystrophy Association Clinical & Scientific Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos to Commence Trading on the Toronto Stock Exchange
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX:MSCL
Satellos Announces Promising Preliminary Data in Facioscapulohumeral Muscular Dystrophy
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX-V:MSCL
Satellos Receives Conditional Approval to Graduate to the Toronto Stock Exchange
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX-V:MSCL
Satellos Bioscience Announces 2023 Q3 Financial Results and Operational Highlights
From Satellos Bioscience Inc.
Via Business Wire
Tickers TSX-V:MSCL
Satellos to Present at the Piper Sandler 35th Annual Healthcare Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX-V:MSCL
Satellos Discloses Drug Target and Provides Development Update on Duchenne Muscular Dystrophy Program
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX-V:MSCL
Satellos to Present at the Stifel 2023 Healthcare Conference
From Satellos Bioscience Inc.
Via Business Wire
Tickers MSCLF TSX-V:MSCL
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.